Literature DB >> 936380

Regression of prostatic cancer metastasis by high doses of diethylstilbestrol diphosphate.

L P Susan, R B Roth, W C Adkins.   

Abstract

Diethylstilbestrol diphosphate (DES-P) has shown effective symptomatic relief in patients with metastatic carcinoma of the prostate. Although there is little known about its role in soft tissue metastasis, our experience in 3 patients with advanced carcinoma of the prostate infiltrating the trigone and ureterovesical junction revealed significant improvement of hydronephrosis. All patients failed to respond to conventional doses of stilbestrol. Diethylstilbestrol diphosphate is recommended in the treatment of advanced carcinoma of the prostate with soft tissue metastasis. It is safe and effective, and the tumor responses outweigh the side effects of the drug. The mechanism of action of this compound is discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 936380     DOI: 10.1016/0090-4295(76)90084-4

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Dose/response study of the effects of oestrogens on tumour growth and morphology in the Dunning R3327 prostatic adenocarcinoma.

Authors:  M Landström; J E Damber; A Bergh; R Tomic
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Adenocarcinoma of the prostate in perspective.

Authors:  A W Bruce; D E Mahan
Journal:  Can Med Assoc J       Date:  1978-11-04       Impact factor: 8.262

Review 3.  Human steroid biosynthesis for the oncologist.

Authors:  Mary Louise Auchus; Richard J Auchus
Journal:  J Investig Med       Date:  2012-02       Impact factor: 2.895

4.  Direct effects of oestradiol on growth and morphology of the Dunning R3327H prostatic carcinoma.

Authors:  L Daehlin; A Bergh; J E Damber
Journal:  Urol Res       Date:  1987

5.  Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study.

Authors:  Andrea N Leaf; Kathleen Propert; Chris Corcoran; Paul J Catalano; Donald L Trump; Jules E Harris; Thomas E Davis
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

6.  Androgen receptor variants: another twist in the plot.

Authors:  Jill A Macoska
Journal:  Oncotarget       Date:  2017-03-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.